Welcome to our dedicated page for Opthea news (Ticker: OPT), a resource for investors and traders seeking the latest updates and insights on Opthea stock.
Opthea Limited (ASX: OPT) generates frequent news as a clinical-stage biopharmaceutical company developing therapies for retinal diseases such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Company announcements describe the progress of its lead product candidate, sozinibercept, a first-in-class VEGF-C/D ‘trap’ inhibitor studied in combination with standard-of-care anti-VEGF-A therapies.
News items for OPT commonly cover clinical milestones, including Phase 2b and Phase 3 trial updates in wet AMD, early-stage data in DME, and presentations of trial results and subgroup analyses at scientific meetings and in peer-reviewed journals. Opthea also releases updates on manufacturing activities, such as completion of drug substance and drug product Process Performance Qualification campaigns to support potential regulatory filings.
Investors following OPT news will also see corporate and capital markets developments. These include half-year financial reports, cash runway commentary, capital raising outcomes, and details of a Development Funding Agreement and its subsequent settlement. The company has reported that primary endpoints were not met in its COAST and ShORe Phase 3 wet AMD trials and has described the decision, together with its DFA investors, to discontinue development of sozinibercept in wet AMD, along with workforce reductions, management changes, and a planned strategic review.
Regulatory and listing updates also appear in Opthea’s news flow, such as announcements related to its intention to voluntarily delist American Depositary Shares from The Nasdaq Global Select Market. For readers interested in the intersection of ophthalmology, clinical trial data, and biotech corporate strategy, the OPT news feed provides ongoing context on Opthea’s programs and corporate actions.
Opthea has successfully completed the institutional component of its capital raising, generating approximately A$171.5 million (US$113.2m). This includes an institutional placement and an entitlement offer. Eligible institutional shareholders took up around 61.4% of their entitlements. The company plans to issue about 428.7 million new shares at A$0.40 each, with the underwriter receiving 55.4 million shares. Additionally, a retail entitlement offer aims to raise A$55.9 million (US$36.9m) between June 19 and July 10, 2024.
The funds will support Opthea through Phase 3 trials of sozinibercept for wet AMD, expected to deliver results by mid-2025, and will also be used for manufacturing, regulatory preparations, and general corporate purposes. Participants in the offer will receive options exercisable at A$1.00, expiring on June 30, 2026. The Retail Entitlement Offer is fully underwritten and details are provided in the Prospectus available on Opthea's website.
Opthea (ASX/NASDAQ: OPT) has announced a capital raising initiative to secure up to A$227.3 million (US$150 million). This includes a A$10 million placement and a A$217.3 million Accelerated Non-Renounceable Entitlement Offer (ANREO). The raised funds will support the Phase 3 clinical trials of sozinibercept for wet AMD, with topline data expected in early and mid-2025. The capital will also progress chemistry, manufacturing, and Biologics License Application (BLA) preparations for FDA approval. The offer price is set at A$0.40 per share, representing discounts to recent trading prices. MST Financial Services will act as the placement agent and lead manager, with BofA Securities and Leerink Partners advising the transactions.
Opthea, a clinical-stage biopharmaceutical company, will present at the Clinical Trials at the Summit (CTS) Meeting in Park City, Utah, on June 8, 2024. Key presentations will include discussions by CEO Frederic Guerard, and scientific presentations by Megan Baldwin and Julie Clark, focusing on the sozinibercept (OPT-302) clinical trial program for wet age-related macular degeneration (wet AMD). The CTS meeting is a significant event that gathers global experts to discuss the latest clinical trials and advancements in vitreoretinal care.
Opthea announced the completion of enrollment for its pivotal Phase 3 clinical program with sozinibercept for wet age-related macular degeneration (wet AMD). The program includes two trials, COAST and ShORe, enrolling 1,984 patients combined. These trials aim to replicate the superior visual outcomes demonstrated in the Phase 2b study. Topline data is anticipated by mid-2025. The trials will compare the efficacy and safety of sozinibercept combined with standard anti-VEGF-A therapies against standard care alone. The primary endpoint is the mean change in Best Corrected Visual Acuity (BCVA) over 52 weeks, with ongoing safety evaluations for up to two years.
Opthea (OPT) announced its participation in the Retina World Congress 2024 to present scientific updates on sozinibercept (OPT-302) Phase 2 trial results and Phase 3 program. CEO Frederic Guerard and other key professionals will discuss the latest advancements in wet age-related macular degeneration treatment.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.